Skip to main content

venBio Global Strategic Fund IV, L.P.'s Form 4 filing

Attovia Therapeutics, Inc. (ATTO) · filed Aug 10, 2026

Accession no.
0000905148-26-003548
Filed
Aug 10, 2026, 4:12 PM ET
Trade date
Aug 6, 2026
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market purchases total $6.50M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
venBio Global Strategic Fund IV, L.P.CIK 000186210910% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 6, 2026Common StockCConversionAcquired+2,311,870––2,311,870Direct
Aug 6, 2026Common StockCConversionAcquired+821,998––3,133,868Direct
Aug 6, 2026Common StockCConversionAcquired+665,147––3,799,015Direct
Aug 6, 2026Common StockPPurchaseAcquired+382,352$17.00+$6,499,9844,181,367Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 6, 2026Common StockCConversionDisposed−2,311,870$0.00$00Direct
Aug 6, 2026Common StockCConversionDisposed−821,998$0.00$00Direct
Aug 6, 2026Common StockCConversionDisposed−665,147$0.00$00Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)